Company intelligence / Profile preview
Guangdong Leiyunshang Pharmaceutical
Likely Guangzhou or another major city in Guangdong province (exact city not confirmed), Guangdong Sheng, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Guangdong Leiyunshang Pharmaceutical has commercialized at least one product—Xueshuantong Injection—for brain infarction in China. Another product, Bufei Huoxue Capsule for chronic obstructive pulmonary disease, has reached Phase 2 clinical trials as of May 2025. The company focuses on traditional Chinese medicine-based therapies and maintains a pipeline in both approved and investigational stages[2][6].
- Therapeutic areas
- PulmonologyNeurologyCardiovascular
- Modalities
- Herbal medicine
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Guangdong Leiyunshang Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangdong Leiyunshang Pharmaceutical.